This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Q3 Earnings, Econ Data Deluge: TWTR, CMCSA, MRK & More
by Mark Vickery
Plenty of grist for the mill this morning, with a heavy inflow of earnings data joining several key economic data reads.
J&J Intends to Buy Residual Stake in Japanese Skincare Firm
by Zacks Equity Research
Johnson & Johnson (JNJ) makes a tender offer to buy the leftover stake in Japanese skincare firm Ci:z Holdings for about $2.05 billion in cash to strengthen its dermatology portfolio.
Merck (MRK) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 2.59% and -0.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Healthcare ETFs to Buy Ahead of Q3 Earnings
by Sweta Killa
The positive estimate revisions suggest continued outperformance for the healthcare ETFs.
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.
Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.
Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC
by Zacks Equity Research
The FDA defers decision by three months regarding the sBLA of Bristol-Myers' (BMY) Opdivo in combination with Yervoy for the treatment of metastatic first-line NSCLC.
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
by Zacks Equity Research
We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive third-quarter sales. However, genericization of key drugs and increasing competition are concerns.
The Zacks Analyst Blog Highlights: United Parcel, Merck, BHP, Energy Transfer and Parker-Hannifin
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United Parcel, Merck, BHP, Energy Transfer and Parker-Hannifin
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $72.35, moving +0.19% from the previous trading session.
Agios Rides on Tibsovo Approval Amid Reliance on Celgene
by Zacks Equity Research
Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.
Alkermes Boasts Strong Portfolio and Impressive Pipeline
by Zacks Equity Research
Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.
Top Stock Reports for UPS, Merck & BHP Billiton
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including United Parcel Service (UPS), Merck (MRK) and BHP Billiton (BHP).
Bio-Techne Partners Micropoint Bioscience, Expands in China
by Zacks Equity Research
Bio-Techne (TECH) believes that its Chinese collaboration is a strategic fit as it will solidify the integration of microfluidic technology for more apt POC diagnostic tools for precision medicine.
Merck (MRK) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck's Keytruda on a Roll in a Thriving Anti-PD-L1 Market
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
Novo Nordisk (NVO) Faces Pricing Pressure and Competition
by Zacks Equity Research
Novo Nordisk (NVO) faces pricing pressures and intense competition in the Diabetes market.
AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
by Zacks Equity Research
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
J&J (JNJ) Beats Earnings & Sales Estimates in Q3, Ups View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the third quarter of 2018 and raises full-year forecast.
Immune Design to Halt Cancer Vaccine Program, Shares Plunge
by Zacks Equity Research
Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.
This is Why Merck (MRK) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Bristol-Myers Reports Disappointing Data From SCLC Study
by Zacks Equity Research
Bristol-Myers??? (BMY) late-stage study on blockbuster immuno-oncology drug, Opdivo for the treatment of SCLC fails.
3 Large-Cap Pharma Stocks Performing Better Than Industry
by Zacks Equity Research
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.